Januvia and Sudden death - a phase IV clinical study of FDA data
Sudden death is found among people who take Januvia, especially for people who are male, 60+ old, have been taking the drug for 2 - 5 years.
The phase IV clinical study is created by eHealthMe based on reports of 66,138 people who have side effects when taking Januvia from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
66,138 people reported to have side effects when taking Januvia.
Among them, 2,062 people (3.12%) died.
What is Januvia?
Januvia has active ingredients of sitagliptin phosphate. It is often used in diabetes. eHealthMe is studying from 67,270 Januvia users for its effectiveness, alternative drugs and more.
Number of Januvia and Sudden death reports submitted per year:
Time on Januvia when people died *:
Gender of people who died when taking Januvia*:
Age of people who died when taking Januvia *:
Common drugs people take besides Januvia *:
Common side effects people have before they died *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Liao KF, Lin CL, Lai SW, Chen WC, "Sitagliptin use and risk of acute pancreatitis in type 2 diabetes mellitus: a population-based case-control study in Taiwan", European journal of internal medicine, 2016 Jan .
- Belice T, Yuce S, Kizilkaya B, Kurt A, Cure E, "Noncardiac pulmonary edema induced by sitagliptin treatment", Journal of family medicine and primary care, 2014 Jan .
- Misgar, R. A., Bhat, J. A., Wani, A. I., & Bashir, M. I., "Sitagliptin induced splenic infarcts", Clinical Diabetology, 2014 Jan .
- Stricklin SM, Stoecker WV, Rader RK, Hood AF, Litt JZ, Schuman TP, "Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia?)", Dermatology online journal, 2012 Feb .
Expand to all the drugs that have ingredients of sitagliptin phosphate:
- Sudden death and drugs with ingredients of sitagliptin phosphate (1,318 reports)
Alternative drugs to, pros and cons of Januvia:
- Januvia (67,270 reports)
Common Januvia side effects:
- Drug ineffective: 3,347 reports
- Diarrhea: 3,114 reports
- Fatigue (feeling of tiredness): 2,735 reports
- Pancreatitis (inflammation of pancreas): 2,572 reports
- Weakness: 2,512 reports
- Headache (pain in head): 2,496 reports
Browse all side effects of Januvia:a b c d e f g h i j k l m n o p q r s t u v w x y z
COVID vaccines that are related to Sudden death:
- Sudden death in Moderna COVID Vaccine
- Sudden death in Pfizer BioNTech Covid Vaccine
- Sudden death in Johnson and Johnson Covid Vaccine
Common drugs associated with Sudden death:
- Oxycontin: 25,919 reports
- Revlimid: 24,344 reports
- Duragesic: 15,960 reports
- Dilaudid: 15,851 reports
- Percocet: 15,739 reports
- Prolia: 14,914 reports
- Ms contin: 14,867 reports
- Aranesp: 14,840 reports
- Aspirin: 14,746 reports
- Opana: 13,795 reports
All the drugs that are associated with Sudden death:
- Sudden death (4,437 drugs)
Common conditions associated with Sudden death:
- Multiple myeloma: 23,142 reports
- Pain: 20,012 reports
- Primary pulmonary hypertension: 17,771 reports
All the conditions that are associated with Sudden death:
- Sudden death (3,754 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on sitagliptin phosphate (the active ingredients of Januvia) and Januvia (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Phenergan and Abdominal Wall Abscess - 18 seconds ago
- Levofloxacin and Cholecystitis Acute - 22 seconds ago
- Norfloxacin and Atropine drug interaction - 23 seconds ago
- Nitrostat and Serevent drug interaction - 31 seconds ago
- Lomotil and Superior Vena Caval Obstruction - 46 seconds ago
- Ibuprofen and Meningitis Pneumococcal - 52 seconds ago
- Buprenorphine and Agranulocytosis - 59 seconds ago
- Neurontin and Syntocinon drug interaction - a minute ago
- Enlarged Prostate and Prostatitis - a minute ago
- Urinary Incontinence and Pneumonia - a minute ago